New analysis shows that HTA organizations may frequently restrict access to cancer treatments
By Randy Burkholder | June 1, 2018
In health care, who should decide value? In many industrialized countries with single-payer health systems, the answer is “the government.” A new analysis by Avalere illustrates the negative...
Read More
Supreme Court decisions in two cases pave way for IPR reforms
By Nicole Longo | May 31, 2018
At the end of April, the Supreme Court decided two cases concerning the inter partes review (IPR) proceedings enacted as part of the 2011 America Invents Act (AIA). While distinct cases, together...
Read More
New analysis shows negative impact of ICER’s value framework on patient access in Medicare Part B
By Lauren Neves | May 31, 2018
Amidst debate about rising health care costs, some policy-makers have expressed renewed interest in using cost-effectiveness thresholds as the basis for setting coverage and payment policy. But a ...
Read More
New report and resources put cancer in context, showing more than 1,100 medicines and vaccines in development
By Andrew Powaleny | May 30, 2018
In the not too distant past, chemotherapy and radiation were once the only treatments for what remains the second leading cause of death in the United States – cancer. Although the death rates of...
Read More
Researchers bring focus on science and medicine to California’s capital city
By Priscilla VanderVeer | May 29, 2018
Health care issues are often so highly politicized that it’s easy to lose sight of the people behind the scenes, especially the millions of medical professionals that wake up each morning with a...
Read More
ICYMI: Recent survey adds to growing body of research on barriers to innovative payment approaches
By Joe Vandigo | May 29, 2018
A recent study conducted by the Academy of Managed Care Pharmacy (AMCP) and Xcenda found that 71 percent of insurers and 63 percent of biopharmaceutical companies surveyed were interested in...
Read More
Guest post: Ensuring communities have a seat at the table: The importance of diversity in clinical trials
By Guest Contributor | May 25, 2018
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest...
Read More
New treatments could save $396 billion over 10 years, lead to better quality of life for migraine sufferers
By Samantha Dougherty | May 22, 2018
A new study found that if all migraine sufferers used an emerging class of preventative migraine treatments, the United States could save $396 billion in indirect costs over ten years and avoid...
Read More
Despite the current unprecedented pace of biopharmaceutical innovation, patients continue to face rising out-of-pocket costs and other barriers to care. Tomorrow, in partnership with The Atlantic,...
Read More
ICYMI: Orphan drug development brings unique challenges
By Gretta Stone | May 21, 2018
A new report from the Tufts Center for the Study of Drug Development finds that it takes 2.3 years, or 18 percent, longer to develop an orphan drug compared with medicines to treat more common...
Read More
Medicare Monday (100)
340B Spotlight (35)
Cost & Consequence (0)
